Clinical trials: Patients With Diabetes.
Diabetes Mellitus, Type 2
A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea
The primary objective of this study is to monitor the safety profile of Trajenta Duo in Korean patients with type 2 diabetes mellitus (T2DM) in a routine clinical setting.
- Trial name
- NCT01903356
- Testing
- Trajenta duo
- Where
- South Korea
- Volunteers
- 724 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes Mellitus
Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting
The purpose of this study is to evaluate the performance of an insulin pump controlling algorithm while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.
- Trial name
- NCT01401751
- Testing
- Hypoglycemia-Hyperglycemia Minimizer System
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Diabetes Mellitus, Non-Insulin-Dependent
Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)
After 24 weeks of treatment, to assess the A1C-lowering efficacy of sitagliptin 100 mg once daily added to the regimen of patients with inadequate glycemic control on metformin monotherapy
- Trial name
- NCT00875394
- Testing
- sitagliptin phosphate, Comparator: metformin, Comparator: Antidiabetic Standard of Care
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background…
- Trial name
- RECORD (NCT00379769)
- Testing
- Rosiglitazone, Sulfonylurea, Metformin
- Where
- 446 sites in Australia, Belgium and 23 more
- Volunteers
- 4,447 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can improve (decrease) blood glucose values in Asian patients with Type 2 Diabetes who have never been treated with medication or have been on…
- Trial name
- NCT01095653
- Testing
- Dapagliflozin, Metformin
- Where
- 39 sites in China, India and 2 more
- Volunteers
- 1,179 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT01022112
- Testing
- TA-7284-Low, TA-7284-Low-middle, TA-7284-High-middle
- Where
- 6 sites in Japan
- Volunteers
- 383 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"
The purpose of this survey is to determine the onset of new cerebral and cardiovascular events and changes in metabolic syndrome parameters in patients with type 2 diabetes mellitus on long-term pioglitazone (Actos Tablets)…
- Trial name
- NCT02002975
- Testing
- Pioglitazone
- Volunteers
- 18,223 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Study in Patients With Type 2 Diabetes
The study is designed to see if once daily oral dosing of LY2608204 will help control diabetes as measured by the glycosylated fraction of hemoglobin A (HbA1c) level.
- Trial name
- NCT01408095
- Testing
- LY2608204, Glimepiride
- Where
- 38 sites in United States, Austria and 5 more
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
Diabetic Nephropathies
Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.
- Trial name
- NCT05718375
- Testing
- CU01-1001
- Where
- 24 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- Curacle Co., Ltd.
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071975
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Diabetes Mellitus
Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.
The purpose of this study is to evaluate the safety and efficacy of TAK-559, once daily (QD), taken in combination with metformin in treating subjects with type 2 diabetes mellitus
- Trial name
- NCT00762957
- Testing
- TAK-559 and metformin, Metformin
- Volunteers
- 15 people
- Sponsor
- Takeda
Type 1 Diabetes Mellitus
Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting
Feasibility study assessing the ability of an insulin pump-controlling algorithm to minimize hypoglycemia and hyperglycemia in patients with type 1 diabetes in a clinical research setting.
- Trial name
- NCT01638299
- Testing
- Hypo-Hyper Minimizer (HHM) System
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Diabetes Mellitus, Non-Insulin-Dependent
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug…
- Trial name
- NCT01105429
- Testing
- BMS-820132
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2
US Inhaled Insulin Therapeutic Choice Questionnaire Study
This is a questionnaire based study (no study drug is involved) that asks if more patients with uncontrolled type 2 diabetes on diabetes pills will choose insulin as the next treatment choice if inhaled insulin were available in…
- Trial name
- NCT00139763
- Testing
- Educational Materials
- Where
- 42 sites in United States
- Volunteers
- 740 people
- Sponsor
- Pfizer
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
Diabetes Visual Function Supplement Study
This study will evaluate the effects of a novel multi-component dietary supplement on the visual function and retinal structure of patients with diabetes with both no diabetic retinopathy and mild to moderate diabetic…
- Conditions
- Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
- Trial name
- DiVFuSS (NCT01646047)
- Testing
- multi-component nutritional supplement capsules, multi-component dietary supplement
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- ZeaVision, LLC
Cardiovascular Disease, Diabetes
Care China-Diabetes
This multicenter, prospective, observational registry will assess efficacy and safety outcomes associated with percutaneous coronary intervention (PCI) with implantation of the CYPHER Select™+ Sirolimus-eluting Coronary Stents in…
- Trial name
- NCT00938119
- Where
- 46 sites in China
- Volunteers
- 1,603 people
- Sponsor
- Johnson & Johnson Medical, China
Diabetic Nephropathy
Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
The purpose of this study is to evaluate the efficacy of MT-3995 in subjects with diabetic nephropathy, compared with placebo, using urine albumin- to-creatinine ratio (UACR) in the first morning void urine sample as an indicator.
- Trial name
- NCT02517320
- Testing
- MT-3995 Low, MT-3995 Middle, MT-3995 High
- Where
- Japan
- Volunteers
- 293 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes (T2DM)
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
This study is a multicenter, randomized, open, parallel-controlled, Phase III clinical study aimed to evaluate the efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes.
- Trial name
- NCT07046273
- Testing
- F027, Ozempic®
- Volunteers
- 496 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Healthy Volunteers, Diabetes Mellitus, Type 1
A Study of LY2605541 Versus Insulin Glargine on Blood Sugar
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, what effect this investigational drug has on the…
- Trial name
- NCT01654380
- Testing
- LY2605541, Insulin glargine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Fatty Liver, Non-Alcoholic Steatohepatitis
A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
This is a multicenter, Phase IIb, randomized, double blind, placebo-controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects that are 18 to 75 years of age, with Non-Alcoholic…
- Conditions
- Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses
- Trial name
- Aramchol_005 (NCT02279524)
- Testing
- Aramchol
- Where
- 78 sites in United States, Chile and 9 more
- Volunteers
- 247 people
- Sponsor
- Galmed Research and Development, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.